USFDA concludes GMP inspection at Piramal Pharma’s USA facility

12 Dec 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded general Good Manufacturing Practices (GMP) inspection at Piramal Pharma’s Lexington (Kentucky, USA) facility. The inspection was conducted from December 03, 2025 to December 10, 2025.

At the conclusion of the inspection, the USFDA issued a Form-483, with four observations. These observations are related to enhancement in procedures and will be classified as a VAI (voluntary action indicated). The Company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

171.70 -2.80 (-1.60%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×